
The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a non-surgical option for idiopathic intracranial hypertension. [WATCH TIME: 3 minutes]
The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a non-surgical option for idiopathic intracranial hypertension. [WATCH TIME: 3 minutes]
New findings reveal the promising efficacy and safety of a subcutaneous lecanemab autoinjector for early Alzheimer disease treatment, enhancing patient care.
The advisory board member of the Parkinson's Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]
At CMSC 2025, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the National MS Society, discussed the impact of health and wellness coaching in patients with multiple sclerosis.
The professor of molecular neurology at the University of Cambridge highlighted recent research on tau protein aggregation in Alzheimer disease and other related tauopathies. [WATCH TIME: 6 minutes]
A real-world study reveals lecanemab's effectiveness in early Alzheimer's, showing stability or improvement in 83.6% of patients after two years.
Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.
UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.
The director of neurosurgical pain division at Allegheny General Hospital highlighted the push to intervene earlier with neurosurgical treatments for chronic pain, including diabetic neuropathy. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]
A groundbreaking phase 2 study evaluates PRI-002's potential to treat mild Alzheimer symptoms, aiming for significant safety and efficacy insights by 2026.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on anti-amyloid treatments for Alzheimer disease.
Valiltramiprosate shows promising effects on brain structure and cognitive function in early Alzheimer disease, highlighting its potential for MCI treatment.
Neurology News Network. for the week ending August 2, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 1, 2025.
Roche's Elecsys pTau181 blood test gains CE Mark, enhancing early Alzheimer’s diagnosis and improving patient outcomes across the European Union.
The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]
Incannex's IHL-42X shows promising results in treating obstructive sleep apnea, demonstrating significant improvements in key metrics and a strong safety profile.
New phase 2 data reveals AR1001's potential as a cognitive enhancer and disease-modifying therapy for mild to moderate Alzheimer's disease.
New data reveals lecanemab's long-term benefits for early Alzheimer's patients, showcasing improved cognitive outcomes and promising safety profiles over four years.
New findings reveal racial disparities in Alzheimer’s trial eligibility, highlighting higher screen failure rates among Black participants in the Auτonomy study.
The senior data scientist at Linus Health discussed how acoustic and speech-based metrics can be used to capture subtle cognitive signals during neuropsychological assessments. [WATCH TIME: 6 minutes]
AAV2-BDNF gene therapy shows promise in reversing cognitive decline in early Alzheimer's, enhancing neuronal function and safety in initial trials.
Navigating the transition from pediatric to adult neurology involves careful planning, education, and support to ensure optimal care and independence for young adults.
Capricor Therapeutics navigates FDA challenges for deramiocel, aiming to advance treatment for DMD-related cardiomyopathy with promising trial data.
The chief scientific officer at Neurogen Biomarking outlined a novel home-based diagnostic model that can accelerate detection of early AD through biomarker profiling. [WATCH TIME: 5 minutes]
The associate professor in the Department of Psychiatry at McGill University discussed the strengths and limitations of PET and blood biomarkers in identifying early Alzheimer disease.
Phase 2 VIVA-MIND study shows varoglutamstat is safe for early Alzheimer’s patients but fails to improve cognitive outcomes.
A new analysis revealed structural brain differences among patients with breast cancer who experienced chemotherapy-associated cognitive impairment following anthracycline-taxane treatment.